<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04601610</url>
  </required_header>
  <id_info>
    <org_study_id>KN046-208</org_study_id>
    <nct_id>NCT04601610</nct_id>
  </id_info>
  <brief_title>KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma</brief_title>
  <official_title>An Open, Multi-center, Ib/II Clinical Trial of KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Alphamab Biopharmaceuticals Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sunshine Lake Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu Alphamab Biopharmaceuticals Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open, multi-center clinical trial, the purpose is to study the safety and&#xD;
      preliminary efficacy of KN046 combined with Ningatinib in subjects with advanced&#xD;
      hepatocellular carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of dose escalation and dose expansion, the mTPI-2 (Modified Toxicity&#xD;
      Probability Interval) will be used for dose exploration. The preset dose of KN046 is 5 mg/kg&#xD;
      Q3W and the preset dose of ningatinib is 10 mg (rapid titration), 20 mg QD, 30 mg QD, and 40&#xD;
      mg QD.Dose expansion will be divided into two cohorts, cohort 1 will enroll subjects who have&#xD;
      not received system therapy and cohort 2 will enroll subjects who have previously received at&#xD;
      least first-line system therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2020</start_date>
  <completion_date type="Anticipated">June 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 8, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DLT</measure>
    <time_frame>1 months</time_frame>
    <description>Dose limit toxicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>1 years</time_frame>
    <description>objective response rate (ORR) based on the RECIST 1.1 by investigator</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>1.5 years</time_frame>
    <description>progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>3 years</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Advanced HCC</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who have not received first-line system treatment previously;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who have received at least first-line system treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KN046 （PD-L1/CTLA4 BsAb）</intervention_name>
    <description>KN046 5mg/kg Q3W</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ningetinib Tosylate（multi-target TKI）</intervention_name>
    <description>ningtinib QD, dose will be decided by investigator</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has a diagnosis of hepatocellular carcinoma confirmed by histology or cytology；&#xD;
&#xD;
          -  Barcelona Clinic Liver Cancer (BCLC) Stage B or C；&#xD;
&#xD;
          -  ECOG performance status: 0-1；&#xD;
&#xD;
          -  Child Pugh score≤7；&#xD;
&#xD;
          -  Enough organ function；&#xD;
&#xD;
          -  Has at least one measurable lesion based on RECIST 1.1；&#xD;
&#xD;
          -  Life expectancy ≥3 months；&#xD;
&#xD;
          -  Patients must be able to understand and willing to sign a written informed consent&#xD;
             document；&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Fibrous lamina hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma,&#xD;
             cholangiocarcinoma etc;&#xD;
&#xD;
          -  Past or present hepatic encephalopathy; or Budd-Chiari syndrome; or Tumor thrombus&#xD;
             invasion at the main portal vein (Vp4), inferior vena cava or heart involvement;&#xD;
&#xD;
          -  Subjects who have previously received immune checkpoint inhibitors (such as&#xD;
             anti-PD-1/L1, CTLA-4, etc.); or have a history of ≥ grade 3 immune-related adverse&#xD;
             reactions; or hyperprogressive after immunotherapy previously；&#xD;
&#xD;
          -  Subjects who have received liver local treatment (transcatheter chemoembolization,&#xD;
             transcatheter embolization, hepatic artery perfusion, radiotherapy, radioembolization&#xD;
             or ablation) within 4 weeks before administration;&#xD;
&#xD;
          -  Subjects who need corticosteroids or immunosuppressive agents for systemic therapy;&#xD;
&#xD;
          -  Any previous or current active autoimmune disease or history of autoimmune disease;&#xD;
&#xD;
          -  History of liver transplantation;&#xD;
&#xD;
          -  History of interstitial lung disease or non-infectious pneumonia;&#xD;
&#xD;
          -  History of allergic reactions to related drugs;&#xD;
&#xD;
          -  LVEF&lt; 50% or LLN&#xD;
&#xD;
          -  Clinically obvious gastrointestinal abnormalities, which may affect the intake,&#xD;
             transport or absorption of drugs (such as inability to swallow, chronic diarrhea,&#xD;
             intestinal obstruction, etc.), or patients undergoing total gastrectomy;&#xD;
&#xD;
          -  With serious systemic diseases such as heart disease and cerebrovascular disease, and&#xD;
             the condition is unstable or uncontrollable;&#xD;
&#xD;
          -  Subjects with clinically significant gastrointestinal bleeding or thrombosis or&#xD;
             embolic events within 6 months;&#xD;
&#xD;
          -  Untreated hepatitis infection: HBV DNA&gt;2000IU/ml or10000 copies/ml, HCV RNA&gt;&#xD;
             1000copy/ml, both HbsAg and anti-HCV body are positive;&#xD;
&#xD;
          -  Evidence of active pulmonary tuberculosis (TB);&#xD;
&#xD;
          -  Positive test of immunodeficiency virus (HIV) or acquired immunodeficiency syndrome&#xD;
             (AIDS);&#xD;
&#xD;
          -  Pleural effusion, ascites and pericardial effusion with clinical symptoms or needing&#xD;
             drainage;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JianMing Xu, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>307 Hospital of PLA，Beijing，China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>JianMing Xu, Doctor</last_name>
    <phone>010-66947176</phone>
    <email>jmxu2003@yahoo.com</email>
  </overall_contact>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 19, 2020</study_first_submitted>
  <study_first_submitted_qc>October 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2020</study_first_posted>
  <last_update_submitted>October 22, 2020</last_update_submitted>
  <last_update_submitted_qc>October 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

